54.62

0.39% 0.21

Pre-market: 54.41 -0.21 -0.38%

Agios Pharmaceuticals Inc (AGIO)

Overview News Price History Option Chain Financials Discussions Forecast

Agios Pharmaceuticals Inc stock is traded at $54.62, with a volume of 357.25K. It is up +0.39% in the last 24 hours and up +20.04% over the past month. Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development plan for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.

Previous Close:

$54.41

Open:

$54.29

24h Volume:

357.25K

Relative Volume:

0.65

Market Cap:

$3.10B

Revenue:

$32.87M

Net Income/Loss:

$674.31M

P/E Ratio:

-13.83

EPS:

-3.95

Net Cash Flow:

$-330.11M

1W Performance:

-6.79%

1M Performance:

+20.04%

6M Performance:

+64.57%

1Y Performance:

+154.05%

1-Day Range:

$53.79

$55.30

1-Week Range:

$52.09

$58.91

52-Week Range:

$20.96

$62.58

Agios Pharmaceuticals Inc Stock (AGIO) Company Profile

Name

Agios Pharmaceuticals Inc

Sector

Healthcare (1193)

Industry

Biotechnology (683)

Phone

617-649-8600

Address

88 SIDNEY STREET, CAMBRIDGE, MA

Employee

386

Twitter

@AgiosPharma

Next Earnings Date

2024-10-31

Latest SEC Filings

AGIO's Discussions on Twitter

Compare AGIO with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AGIO	54.62	3.10B	32.87M	674.31M	-330.11M	-3.95
VRTX	451.23	115.74B	10.63B	-479.80M	-1.35B	13.33
REGN	743.35	81.65B	13.85B	4.65B	3.32B	35.06
ARGX	591.82	34.86B	1.86B	-40.29M	-1.28B	-4.16
ALNY	248.79	32.09B	2.09B	-332.26M	16.06M	-4.14
BNTX	102.14	24.49B	3.30B	-501.07M	1.03B	11.54

Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-08-24	Initiated	Cantor Fitzgerald	Overweight
Feb-03-23	Initiated	Piper Sandler	Overweight
Nov-17-22	Upgrade	Goldman	Sell → Neutral
Jul-27-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Dec-03-21	Initiated	BofA Securities	Buy
Jul-30-21	Downgrade	Goldman	Neutral → Sell
Jul-01-21	Initiated	Raymond James	Mkt Perform
Jun-10-21	Initiated	H.C. Wainwright	Buy
Mar-01-21	Downgrade	JP Morgan	Overweight → Neutral
Mar-01-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Feb-26-21	Downgrade	SVB Leerink	Outperform → Mkt Perform
Oct-22-20	Upgrade	Barclays	Equal Weight → Overweight
Mar-04-20	Initiated	Barclays	Equal Weight
Nov-26-19	Initiated	Cantor Fitzgerald	Overweight
Sep-23-19	Upgrade	Guggenheim	Neutral → Buy
May-23-19	Resumed	Goldman	Neutral
Feb-15-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-25-18	Initiated	Leerink Partners	Mkt Perform
May-23-18	Initiated	Citigroup	Buy
Apr-11-18	Reiterated	Credit Suisse	Outperform
Feb-15-18	Reiterated	Needham	Buy
Feb-15-18	Reiterated	SunTrust	Buy
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Aug-10-17	Reiterated	Needham	Buy
Aug-08-17	Reiterated	SunTrust	Buy
Aug-02-17	Upgrade	Leerink Partners	Mkt Perform → Outperform
Jun-26-17	Downgrade	Janney	Buy → Neutral
Jan-17-17	Upgrade	Oppenheimer	Perform → Outperform
Oct-24-16	Initiated	Needham	Buy
Jun-13-16	Upgrade	JP Morgan	Neutral → Overweight
May-18-16	Reiterated	SunTrust	Buy

View All

Agios Pharmaceuticals Inc Stock (AGIO) Latest News

05:06 AM

(AGIO) Pivots Trading Plans and Risk Controls - Stock Traders Daily

05:06 AM

Nov 20, 2024

C4 Therapeutics Appoints Accomplished Oncology Executive Steve Hoerter to Board of Directors - GlobeNewswire Inc.

Nov 20, 2024

Nov 17, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Sees Significant Growth in Short Interest - MarketBeat

Nov 17, 2024

Nov 16, 2024

Brokerages Set Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Price Target at $52.33 - MarketBeat

Nov 16, 2024

Nov 14, 2024

ARMISTICE CAPITAL, LLC Expands Portfolio with Agios Pharmaceuticals Inc - GuruFocus.com

Nov 14, 2024

Nov 12, 2024

Agios Pharmaceuticals director sells shares worth $1.12 million By Investing.com - Investing.com Canada

Nov 12, 2024

Agios Pharmaceuticals chief legal officer sells $1.14 million in stock - Investing.com India

Nov 12, 2024

Agios Pharmaceuticals chief legal officer sells $1.14 million in stock By Investing.com - Investing.com UK

Nov 12, 2024

Nov 09, 2024

StockNews.com Upgrades Agios Pharmaceuticals (NASDAQ:AGIO) to Hold - MarketBeat

Nov 09, 2024

Nov 08, 2024

Agios stock soars to 52-week high, reaching $53.28 By Investing.com - Investing.com Canada

Nov 08, 2024

Nov 07, 2024

Agios stock soars to 52-week high, reaching $53.28 - Investing.com

Nov 07, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance

Nov 07, 2024

Nov 05, 2024

Agios Pharmaceuticals' SWOT analysis: promising pipeline, cash boost fuel stock outlook - Investing.com India

Nov 05, 2024

Mirae Asset Global Investments Co. Ltd. Acquires 363 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) - Defense World

Nov 05, 2024

Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition - The Manila Times

Nov 05, 2024

Agios to Unveil Critical Phase 3 Data for Blood Disorder Drugs at ASH 2024 | AGIO Stock News - StockTitan

Nov 05, 2024

Nov 04, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Shares Sold by Assenagon Asset Management S.A. - MarketBeat

Nov 04, 2024

Nov 03, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Rating Lowered to “Sell” at StockNews.com - Defense World

Nov 03, 2024

Nov 02, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Downgraded to "Sell" Rating by StockNews.com - MarketBeat

Nov 02, 2024

Nov 01, 2024

Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (6 Ratings) - Benzinga

Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given "Outperform" Rating at Royal Bank of Canada - MarketBeat

Nov 01, 2024

AGIO's Q3 Earnings Miss Mark, Revenues In Line, Stock Down - Yahoo Finance

Nov 01, 2024

Agios Pharmaceuticals (NASDAQ:AGIO) Given New $53.00 Price Target at Scotiabank - MarketBeat

Nov 01, 2024

Agios shares hold Strong Buy rating, $51 target from Raymond James - Investing.com Australia

Nov 01, 2024

Earnings call: Agios Pharmaceuticals reports Q3 2024 financials, plans launches - Investing.com Australia

Nov 01, 2024

Is ADC Therapeutics (ADCT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Nov 01, 2024

Agios Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance

Nov 01, 2024

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 01, 2024